Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 5/20 | 1.00 |
| ▸ | CA1 known ✓ | P00915 | 3/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.64 |
| ▸ | TSHR | P16473 | 2/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.64 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.47 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | LCK | P06239 | 1/20 | 0.45 |
| ▸ | PPARD | Q03181 | 1/20 | 0.45 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.45 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15387920 | 0.98 | CA2 (0.96) | CA2NFKB1CYP3A4TSHRNPSR1 | |
| SCHEMBL689372 | 0.98 | CA2 (0.96) | CA2NFKB1CYP3A4TSHRNPSR1 | |
| SCHEMBL4254221 | 0.98 | CA2 (0.96) | CA2NFKB1CYP3A4TSHRNPSR1 | |
| SCHEMBL5496573 | 0.98 | CA2 (0.96) | CA2NFKB1CYP3A4TSHRNPSR1 | |
| SCHEMBL15387978 | 0.98 | CA2 (0.96) | CA2NFKB1CYP3A4TSHRNPSR1 | |
| SCHEMBL15387890 | 0.98 | CA2 (0.96) | CA2NFKB1CYP3A4TSHRNPSR1 | |
| SCHEMBL5704847 | 0.98 | CA2 (0.96) | CA2NFKB1CYP3A4TSHRNPSR1 | |
| SCHEMBL15387941 | 0.98 | CA2 (0.96) | CA2NFKB1CYP3A4TSHRNPSR1 | |
| SCHEMBL1963319 | 0.98 | CA2 (0.96) | CA2NFKB1CYP3A4TSHRNPSR1 | |
| SCHEMBL321981 | 0.98 | CA2 (0.96) | CA2NFKB1CYP3A4TSHRNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1390383-B1 | ANTISENSE PERMEATION ENHANCERS | ISIS PHARMACEUTICALS INC (US) | 2012-02-29 | — | — | EP | claimed |
| US-8039444-B2 | Antisense permeation enhancers | ISIS PHARMACEUTICALS, INC. (US) | 2011-10-18 | — | — | US | claimed |
| EP-1390383-A4 | ANTISENSE PERMEATION ENHANCERS | ORASENSE LTD (BM) | 2008-07-09 | — | — | EP | claimed |
| US-20070004668-A1 | Antisense permeation enhancers | IONIS PHARMACEUTICALS, INC. | 2007-01-04 | — | — | US | claimed |
| JP-2004537516-A | — | — | 2004-12-16 | — | — | JP | claimed |
| EP-1390383-A1 | ANTISENSE PERMEATION ENHANCERS | Orasense, Ltd. (BM) | 2004-02-25 | — | — | EP | claimed |
| US-20030176379-A1 | Useful in the administration of a drug, therapy | ISIS PHARMACEUTICALS, INC. | 2003-09-18 | — | — | US | claimed |
| WO-2002092616-A1 | ANTISENSE PERMEATION ENHANCERS | ORASENSE, LTD. (BM) | 2002-11-21 | — | — | WO | claimed |
| EP-2928999-B1 | CLEANING COMPOSITION | COLGATE PALMOLIVE CO (US) | 2016-12-07 | — | — | EP | disclosed |
| EP-1390383-B1 | ANTISENSE PERMEATION ENHANCERS | ISIS PHARMACEUTICALS INC (US) | 2012-02-29 | — | — | EP | disclosed |
| US-8039444-B2 | Antisense permeation enhancers | ISIS PHARMACEUTICALS, INC. (US) | 2011-10-18 | — | — | US | disclosed |
| EP-1390383-A4 | ANTISENSE PERMEATION ENHANCERS | ORASENSE LTD (BM) | 2008-07-09 | — | — | EP | disclosed |
| US-20070004668-A1 | Antisense permeation enhancers | IONIS PHARMACEUTICALS, INC. | 2007-01-04 | — | — | US | disclosed |
| EP-1390383-A1 | ANTISENSE PERMEATION ENHANCERS | Orasense, Ltd. (BM) | 2004-02-25 | — | — | EP | disclosed |
| US-20030176379-A1 | Useful in the administration of a drug, therapy | ISIS PHARMACEUTICALS, INC. | 2003-09-18 | — | — | US | disclosed |
| WO-2002092616-A1 | ANTISENSE PERMEATION ENHANCERS | ORASENSE, LTD. (BM) | 2002-11-21 | — | — | WO | disclosed |
| US-5736503-A | High sudsing detergent compositions with specially selected soaps | THE PROCTER & GAMBLE COMPANY (US) | 1998-04-07 | — | — | US | disclosed |
| WO-1994012608-A1 | HIGH SUDSING DETERGENT COMPOSITIONS WITH SPECIALLY SELECTED SOAPS | THE PROCTER & GAMBLE COMPANY (US) | 1994-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004668-A1 | Antisense permeation enhancers | SLC22A8, SLCO1B1, SLCO2B1 | CA2 2174/4885CA1 3793/4885NFKB1 3719/4885 |
| US-20030176379-A1 | Useful in the administration of a drug, therapy | SLC19A1, POLRMT, SNRPE | CA2 2883/4885CA1 3441/4885NFKB1 3845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.